IGF1R and neoplasm: A total of 10 studies (42%) combined anti-IGF-1R mAbs with other agents, including mTOR inhibitors (n = 5, 21%), chemotherapy (n = 2, 8%), cyclin-dependent kinase (CDK) 4/6 inhibitors (n = 1, 4%), pegvisomant (n = 1, 4%), and one ongoing trial (4%) is exploring microdosing of 10 anti-tumor agents using an intratumoral device.